Cargando…
Selective Serotonin Reuptake Inhibitor Use and Risk of Major Bleeding during Treatment with Vitamin K Antagonists: Results of A Cohort Study
Background Selective serotonin reuptake inhibitors (SSRIs) may increase the risk of major bleeding by decreasing platelet function or decreasing vitamin K antagonist (VKA) metabolism via cytochrome P450 (CYP) inhibition. Aims To determine whether SSRIs are associated with major bleeding during VKA...
Autores principales: | Bakker, Sanne, Burggraaf, Johanna Louise I., Kruip, Marieke J. H. A., van der Meer, Felix J. M., Lijfering, Willem M., van Rein, Nienke |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9904966/ https://www.ncbi.nlm.nih.gov/pubmed/36208621 http://dx.doi.org/10.1055/a-1957-6305 |
Ejemplares similares
-
Association of VKORC1 polymorphisms and major bleedings in patients who are treated with vitamin K antagonists
por: van Heteren, D. Max, et al.
Publicado: (2022) -
Objectives and Design of BLEEDS: A Cohort Study to Identify New Risk Factors and Predictors for Major Bleeding during Treatment with Vitamin K Antagonists
por: van Rein, Nienke, et al.
Publicado: (2016) -
Statin use decreases coagulation in users of vitamin K antagonists
por: van Rein, Nienke, et al.
Publicado: (2016) -
Stability of vitamin K antagonist anticoagulation after COVID‐19 diagnosis
por: Camilleri, Eleonora, et al.
Publicado: (2021) -
Switching from vitamin K antagonists to direct oral anticoagulants: Treatment satisfaction and patient concerns
por: Toorop, Myrthe M. A., et al.
Publicado: (2020)